Patrick Spencer, RN, OCN provides important points to cover when counseling a patient with multiple myeloma receiving treatment with daratumumab.
Patrick Spencer, RN, OCN, of Mount Sinai Medical Center, provides some important points to cover when counseling a patient with multiple myeloma receiving treatment with daratumumab.
The first day especially requires long hours of infusion. Spencer also recommends that the patient bring a caregiver with them. There can be infusion-related reactions that a patient might not normally report, such as a runny nose or itchy throat. If patients are prepared, however, and know to inform their clinicians, they can receive the proper medication to prevent such reactions from becoming severe.
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.